ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
IMA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
ImageneBio IncNASDAQ: IMA
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses dips below year-ago levels
Q1 FY2026 other income / expenses of $1.47M fell 33.3% year over year, behind the +5.4% change in trailing-twelve-month other income / expenses. Sequentially, it rose 11.4% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.
Context
- Other income / expenses amounted to 344.0% of revenue in FY2025, up 331.3 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -33.3% toward the trailing-twelve-month pace of +5.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 2.75M USD
- Year-over-year change
- +518.4%
- 4-year CAGR
- +230.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.75M | +518.4% |
| FY2024 | 2024-12-31 | 445K | -93.7% |
| FY2023 | 2023-12-31 | 7.09M | +231.4% |
| FY2022 | 2022-12-31 | 2.14M | +9200.0% |
| FY2021 | 2021-12-31 | 23K | — |
Other Income / Expenses vs competitors
How IMA compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.4% is the 2nd highest of 9, against a peer median of -42.9%.
- Over three fiscal years its annual growth of +8.8% compares with a peer median of +45.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.57M USD | -26.4% | +162.8% | 330.9% | |
IMAImageneBio Inc | LTM Mar 2026 | $10.53M USD | +5.4% | +8.8% | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $5M USD | -50.6% | +65.3% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $3.53M USD | +1344.0% | — | — |
| LTM Mar 2026 | $3.29M USD | -17.6% | +87.2% | — | |
| FY2025 | $2.79M USD | -60.4% | +22.4% | 4360.9% | |
| LTM Mar 2026 | $2.79M USD | -35.2% | +24.9% | 279.0% | |
| LTM Mar 2026 | -€440.14K EUR | -104.4% | -1.4% | 1500.6% | |
| LTM Mar 2026 | -$38.64M USD | -613.7% | — | 38.8% | |
| Peer median (excluding IMA) | — | -42.9% | +45.1% | 330.9% | |
Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.99M | 15.62M | 9.16M | 3.5M | 800K |
| Cost of Revenue | 47.11M | 64.32M | 1.02M | 1.53M | 1.03M |
| Gross Profit | (16.12M) | (48.7M) | 8.14M | 3.5M | (233K) |
| Gross Margin | -52.0% | -311.8% | 88.9% | 100.0% | -29.1% |
| Research & Development | 47.11M | 64.32M | 59.65M | 32.11M | 28.53M |
| Selling, General & Admin | 18.02M | 22.2M | 24.93M | 8.39M | 20.73M |
| Operating Expenses | 18.02M | 22.2M | 83.56M | 40.5M | 48.22M |
| Depreciation & Amortization | 544K | 751K | 1.02M | 1.53M | 1.03M |
| EBITDA | (33.57M) | (68.01M) | (67.31M) | (35.03M) | (44.67M) |
| EBITDA Margin | -108.3% | -435.5% | -734.8% | -1000.8% | -5583.3% |
| Operating Income | (34.14M) | (70.9M) | (75.42M) | (37M) | (48.45M) |
| Operating Margin | -110.2% | -454.0% | -823.3% | -1057.1% | -6056.4% |
| Interest Income | 23K | 2.15M | 7.11M | 7.37M | 2.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 23K | 2.14M | 7.09M | 445K | 2.75M |
| Income Before Tax | (34.12M) | (68.77M) | (68.33M) | (36.56M) | (45.7M) |
| Pre-Tax Margin | -110.1% | -440.3% | -745.9% | -1044.4% | -5712.4% |
| Income Tax Expense | 0 | 0 | (162K) | 13K | (350K) |
| Net Income | (34.12M) | (68.77M) | (68.17M) | (36.57M) | (45.35M) |
| Net Margin | -110.1% | -440.3% | -744.2% | -1044.8% | -5668.6% |
| EPS (Basic) | (0.95) | (1.90) | (1.63) | (1.02) | (10.76) |
| EPS (Diluted) | (0.95) | (1.90) | (1.63) | (1.02) | (10.76) |
| Weighted Avg Shares | 35.98M | 36.19M | 41.74M | 48.26M | 4.87M |
| Weighted Avg Shares (Diluted) | 35.98M | 36.19M | 41.74M | 48.26M | 4.87M |
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.